Kestra Private Wealth Services LLC Acquires 5,767 Shares of Boston Scientific Co. (NYSE:BSX)

Kestra Private Wealth Services LLC grew its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 21.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,153 shares of the medical equipment provider's stock after acquiring an additional 5,767 shares during the quarter. Kestra Private Wealth Services LLC's holdings in Boston Scientific were worth $2,961,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of BSX. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in Boston Scientific by 9.7% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider's stock worth $115,000 after buying an additional 119 shares during the period. Adero Partners LLC lifted its position in shares of Boston Scientific by 3.3% during the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after purchasing an additional 120 shares during the last quarter. Grove Bank & Trust increased its holdings in shares of Boston Scientific by 4.4% in the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock valued at $261,000 after acquiring an additional 122 shares during the last quarter. PFG Investments LLC lifted its stake in Boston Scientific by 1.6% during the fourth quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider's stock worth $725,000 after purchasing an additional 125 shares during the last quarter. Finally, Stonegate Investment Group LLC increased its stake in Boston Scientific by 1.6% during the fourth quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider's stock valued at $699,000 after purchasing an additional 126 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Price Performance

NYSE BSX traded down $0.15 on Tuesday, reaching $106.03. 4,830,106 shares of the stock traded hands, compared to its average volume of 6,191,119. Boston Scientific Co. has a 12 month low of $64.54 and a 12 month high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm's fifty day simple moving average is $95.19 and its 200 day simple moving average is $87.50. The company has a market cap of $156.26 billion, a price-to-earnings ratio of 84.82, a P/E/G ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, research analysts predict that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on BSX shares. Truist Financial lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. BTIG Research upped their target price on Boston Scientific from $84.00 to $93.00 and gave the company a "buy" rating in a report on Monday, October 14th. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a report on Thursday, February 6th. Royal Bank of Canada upped their price objective on Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Finally, Canaccord Genuity Group boosted their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a report on Monday, December 9th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $107.39.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP John Bradley Sorenson sold 6,528 shares of Boston Scientific stock in a transaction on Friday, February 7th. The shares were sold at an average price of $104.97, for a total value of $685,244.16. Following the transaction, the executive vice president now owns 26,449 shares in the company, valued at $2,776,351.53. This represents a 19.80 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,830 shares of company stock valued at $5,149,969. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.